Zoetis leads a fragmented companion animal arthritis market

A new market review says the companion animal arthritis market is moderately fragmented, with Zoetis holding the top global sales position in 2024 and the top 10 players controlling 20% of revenue. The report points to growing competition around biologics, regenerative medicine, and easier-to-use pain management products as veterinary care for aging pets evolves.

Why it matters: - The companion animal arthritis market is growing more competitive as pet owners and veterinarians look for better pain control, mobility support, and longer-term joint health solutions. - The report says market leadership will likely hinge on products that improve treatment adherence, extend therapeutic duration, and support chronic care for dogs and cats. - The competitive mix matters because the market combines global animal health firms, nutrition companies, and specialized veterinary therapeutics providers.

What happened: - The Business Research Company published a 2026 market report on the companion animal arthritis market. - Zoetis Inc. led global sales in 2024 with a 2% market share. - The report says the market is moderately fragmented. - The top 10 players accounted for 20% of total market revenue in 2024. - Leading companies listed in the report include Zoetis Inc., Merck Animal Health, Boehringer Ingelheim, Virbac, Dechra Pharmaceuticals, Vetoquinol, Bayer Animal Health, Nutramax Laboratories, Hill's Pet Nutrition, and Royal Canin. - The report identifies major raw material suppliers, wholesalers and distributors, and end users across the companion animal arthritis value chain.

The details: - Zoetis' companion animal portfolio includes osteoarthritis pain management therapies, monoclonal antibody treatments, anti-inflammatory products, and veterinary healthcare solutions. - The portfolio is positioned around mobility improvement, chronic pain control, quality of life, and long-term arthritis management in canine and feline patients. - Other major raw material suppliers include Evonik Industries AG, DSM-Firmenich, Kerry Group plc, Ingredion Incorporated, Cargill Incorporated, Kemin Industries, Balchem Corporation, Gelita AG, Rousselot, Givaudan SA, ADM Animal Nutrition, Novonesis A/S, Lonza Group AG, Corbion N.V., Roquette Frères, Ashland Inc., Bioiberica S.A.U., Aker BioMarine ASA, and Seagarden AS. - Major wholesalers and distributors include Covetrus Inc., Patterson Veterinary Supply, MWI Animal Health, Penn Veterinary Supply, Victor Medical Company, Midwest Veterinary Supply, VetSource, Kruuse, Agrihealth, VetPlus Distribution, Independent Vetcare Distribution Services, Medcare Vet Supplies, Direct-Vet Marketing, Veterinary Instrumentation, DMS Veterinary Supplies, Pet Drugs Online, Boehringer Ingelheim Animal Health Distribution, Zoetis Distribution Networks, Elanco Logistics, and Merck Animal Health Supply Channels. - Major end users include Banfield Pet Hospital, VCA Animal Hospitals, BluePearl Pet Hospital, MedVet, National Veterinary Associates, AniCura, IVC Evidensia, Greencross Vets, CVS Group plc, Linnaeus Veterinary Limited, Southern Veterinary Partners, PetVet Care Centers, Animal Trust, VetPartners Australia, Heart + Paw, Bond Vet, VEG, Petco Veterinary Services, PDSA, and RSPCA Veterinary Hospitals. - The report highlights new features in its 2026 editions, including market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report also says it uses 1,500,000 datasets, secondary research, and interviews with industry leaders.

Between the lines: - The market structure suggests no single player dominates, even though several major brands hold similar share levels. - The focus on biologics, regenerative medicine, targeted anti-inflammatories, and nutritional supplements shows the category is broadening beyond traditional drug therapy. - Zoetis' launch of Bonqat in April 2024 for feline acute anxiety and fear around transport and vet visits shows how easier clinic access can support broader care engagement, including follow-up treatment for chronic conditions. - That kind of product strategy can help companies build repeated contact with pet owners and veterinary clinics, which matters in long-term arthritis management.

What's next: - The report expects product innovation, strategic collaborations, and expansion of veterinary care offerings to shape competitive positioning. - Companies are likely to keep investing in advanced biologic therapies, personalized veterinary care, regenerative medicine, joint-support supplements, and pain-relief products. - The report's detailed market forecast runs through 2035. - More information is available in the company's announcement and the sample request.

The bottom line: - Companion animal arthritis is a fragmented but expanding veterinary category, and the winners are likely to be companies that combine clinical efficacy with easier administration and long-term care support.